{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', 'Medications that are allowed, provided that conditions outlined in the table are met, are shown in Table 5. Tables for allowed and', 'prohibited medications are not exhaustive and may not include all possible concomitant medications.', 'The', 'medical', 'monitor must be contacted if a patient is receiving (or has to begin or stop receiving during the study) a medication that is', 'associated with QTc prolongation or that is a known strong cytochrome P450 inhibitor, or if there are any questions', 'regarding', 'any', 'medication not listed in the tables below.', 'Prohibited medications that are associated with QTc prolongation are listed in Table 6, while prohibited antipsychotic drugs are listed', 'in Table 7.', 'Table 5:', 'Allowed Medications', 'Generic/Drug class', 'Condition', 'Stable medications allowed according to inclusion/exclusions criteria', 'Hormonal birth control', 'Must be receiving stable treatment (including dose) for at least 3 months before screening.', 'Antidepressants', 'Must be receiving stable treatment (including dose) for at least 6 weeks before screening.', 'Benzodiazepines', 'Primary use must not be for tics; dosing must have been stable QT for at least 4 weeks before', 'screening.', 'Note: PRN (as needed) use is prohibited.', 'Topiramate', 'Must be receiving stable treatment (including dose) for at least 4 weeks before screening.', '(up to 200 mg/day)', 'Guanfacine', 'Allowed, regardless of indication (ie, if prescribed for ties or Tourette syndrome). Must be', 'receiving stable treatment (including dose) for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation', 'of guanfacine is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'Clonidine', 'Allowed, regardless of indication (ie, if prescribed for tics or Tourette syndrome). Must be', 'receiving stable treatment (including dose) for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation', '205']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Generic/Drug class', 'Condition', 'Stable medications allowed according to inclusion/exclusions criteria', 'of clonidine is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'Stimulants', 'Include amphetamine, methylphenidate, and lisdexamfetamine. Primary use is for the', 'treatment of ADHD; dosing must have been stable for at least 2 weeks before screening and', 'no changes to dose or frequency are anticipated during the course of the study.', 'Table 5:', 'Allowed Medications (Continued)', 'Generic/Drug class', 'Condition', 'SNRIs', 'Includes atomoxetine. Primary use is for the treatment of ADHD; dosing must have been', 'stable for at least 4 weeks before screening and no changes to dose or frequency are', 'anticipated during the course of the study.', 'Additional medications allowed with preapproval from medical monitor', 'Albuterol, levalbuterol', 'Asthma', 'Guaifenesin', 'Cold symptoms', 'Antihistamines', 'Allergies', 'Melatonin', 'Insomnia', 'Allowed strong CYP inhibitors', 'Bupropion', 'Antidepressant (aminoketone)', 'Fluoxetine', 'Antidepressant (selective serotonin reuptake inhibitor)', 'Paroxetine', 'Antidepressant (selective serotonin reuptake inhibitor)', 'a', 'The use of these medications will affect the maximum daily dose of IMP, as shown in Table 2.', 'ADHD=Attention-deficit/hyperactivity disorder; CYP=cytochrome P450; IMP=investigational medicinal product; SNRIs=serotonin-norepinephrine reuptake', 'inhibitor', 'Note: No dosing changes can be made during the study.', '206']\n\n###\n\n", "completion": "END"}